Auris Medical Holding Ltd

EARS NASDAQ
2.772
+0.012
+0.43%
Opening 10:08 06/25 EDT
Open
2.770
Prev Close
2.760
High
2.786
Low
2.737
Volume
11.27K
Avg Vol (3M)
239.37K
52 Week High
39.40
52 Week Low
2.410
% Turnover
0.05%
Market Cap
66.74M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Auris Medical Holding Ltd EARS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
MORE >

Recently

Name
Price
%Change